Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)

The Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years.

According to Publisher research report, "Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)", global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases.

Get Sample Copy of this Report@

Scope of the Report
Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market) analyses the following aspects of global Alzheimer's market:
- Global NASH Market Size, Share & Forecast
- Segmental Analysis - By off Label , By Specific Drug and By Patient
- Policy & Regulatory Landscape
- Changing Market Trends & Emerging Opportunities
- Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?
1. To gain an in-depth understanding of NASH disease and dementia market propelling globally.
2. To identify the on-going trends and anticipated growth in the next five years
3. To help industry consultants, drug and diagnostics manufacturers, vendors and dealers align their market-centric strategies
4. To obtain research based business decision and add weight to presentations and marketing material
5. To gain competitive knowledge of leading players
6. To avail limited customization in the report without any extra charges and get research data or trends added in the report as per the buyer's specific needs

For more information about this [email protected]

Table of Contents:

1. Research Methodology

2. Executive Summary

3. Global NASH Market: An Analysis

3.1 Global NASH Market Overview
3.1.1 Global NAFLD Population
3.1.2 Global NASH Population
3.1.3 Global NASH Population, By Prevalence Rate
3.1.4 Global NASH Diagnosed Cases
3.2 Global NASH Market by Therapeutics
3.3 Global NASH Off-Label Drugs Market by Value
3.4 Global NASH Off-Label Drugs Market Share by Region
3.5 Global GFT505 Market: Sizing & Growth
3.5.1. GFT505 Estimated Valuation
3.5.2. GFT505 Market By Value
3.6. Global Aramchol Market: Sizing & Growth
3.6.1. Market Size: By Value
3.6.2. Market Size: By Patient Volume
3.7. Global GR-MD-02 Market: Sizing & Growth
3.7.1 GR-MD-02 in NASH Patients
3.7.2 GR-MD-02 Market By Value

4. Country Analysis

5. The US NASH Market by Therapeutics

6. Regional Analysis

7. Country Overview

8. Clinical Pipeline Analysis of NASH Drugs

9. Market Dynamics
9.1 Drivers
9.2 Challenges
9.3 Market Trends & Developments

10. Competitive Landscape
10.1 Company Profiling
10.1.1 Galmed Pharmaceuticals
10.1.2 Genfit
10.1.3 Galectin Therapeutics
10.1.4 Gilead Sciences

11. Strategic Recommendations

Inquiry before [email protected]

About Us:

Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more Expert concerns.

Contact Us:

[email protected]

+1 (888) 278-7681

Posted by on Tuesday March 13 2018, 1:18 AM EST. All trademarks acknowledged. Filed under Advanced Materials, Business & Financial Services, Business Services, Chemicals, Chemicals & Materials, Consumer & Retail, Featured Press Release, Metallurgical, Retail, Technology Hardware & Equipment. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

News Categories

Featured Press Releases

Latest News

Log in